Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers

Cancer Control : Journal of the Moffitt Cancer Center
Koichi Suyama, Hirotaka Iwase

Abstract

Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET). These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors. Phase I trials of lenvatinib were conducted at the same time in Japan, Europe, and the United States, and tumor shrinkage effects were observed in thyroid cancer, endometrial cancer, melanoma, renal cell carcinoma, sarcoma, and colon cancer. Lenvatinib is a promising drug that has shown therapeutic effects against various solid tumors. Adverse events, such as hypertension, proteinuria, diarrhea, and delayed wound healing, can occur with lenvatinib treatment. Managing these adverse events is also important for the use of lenvatinib. In this mini-review article, we outline the current state, toxicity, and future prospects of lenvatinib toward thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and lung cancer.

References

Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jul 24, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Ron J KeizerAlwin D R Huitema
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kazuhiko YamadaTomohide Tamura
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Jul 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David S HongJohn Nemunaitis
Aug 28, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin SchlumbergerSteven I Sherman
Oct 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masafumi IkedaHiromitsu Kumada
Nov 5, 2015·Cancer Chemotherapy and Pharmacology·Shinji NakamichiTomohide Tamura
Oct 6, 2016·Journal of Gastroenterology·Kenji IkedaHiromitsu Kumada
Mar 17, 2017·Frontiers in Oncology·Makoto TaharaShunji Takahashi
May 5, 2017·Thyroid : Official Journal of the American Thyroid Association·Nicole M Iñiguez-ArizaKeith C Bible
Jun 15, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marcia S BroseArti Hurria
Jul 8, 2017·Molecular and Clinical Oncology·Koichi SuyamaHirotaka Iwase

❮ Previous
Next ❯

Citations

Aug 14, 2019·Expert Opinion on Emerging Drugs·Claudia Maria HattingerMassimo Serra
Aug 18, 2020·Cancer Control : Journal of the Moffitt Cancer Center·Yu-Shui MaDa Fu
Aug 11, 2020·Frontiers in Cell and Developmental Biology·Christopher Montemagno, Gilles Pagès
Sep 29, 2020·Frontiers in Oncology·Zhichao TianWeitao Yao
Aug 7, 2019·Future Oncology·Alessandro Piovesan
Aug 7, 2019·European Journal of Medicinal Chemistry·Giosuè CostaClaudiu T Supuran
Nov 3, 2020·Expert Review of Gastroenterology & Hepatology·Hui Li
May 5, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaume CapdevilaToni Ibrahim
May 6, 2021·Cancers·Amisha SinghMay Cho
May 30, 2021·Critical Reviews in Oncology/hematology·Stefano FogliRomano Danesi
Jul 16, 2021·Drug Discovery Today·Olívia PontesMarta Costa
Jan 6, 2022·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckMatthew D Hellmann

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
ubiquitination

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.